FIGURE

Figure 2

ID

ZDB-FIG-230609-17

Publication

Sheppard et al., 2023 - Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition

Other Figures

All Figure Page

Back to All Figure Page

Figure 2

A 2D in vitro model of lymphatic dysplasia.

HDLECs were stained with VE-cadherin or actin. Scale bars: 50 ?m. (A) KRAS WT. (B) KRAS p.Gly12Asp. Yellow circles show extensions from cells. (C) KRAS p.Gly12Asp treated with 30 nm trametinib. (D) KRAS p.Gly12Asp treated with 1 ?m binimetinib. Yellow arrows show areas where abnormal extensions remain. (E) Cell lysates from HDLECs transduced with either KRAS WT or p.Gly12Asp were analyzed with IB for pERK at T202 and Y204 or pS6 at S235/236 with actin as control. (F) Quantification of IB, pERK, or pS6 normalized to actin, normalized to WT + DMSO sample. Data were quantitated from 4 independent experiments. Bars are means; error bars are SDs. One-sided Student?s t tests were performed to calculate significance. Bin, binimetinib; Tram, trametinib.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ JCI Insight